^
Association details:
| Biomarker: | YWHAE-ROS1 fusion |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report
Published date:
06/15/2021
Excerpt:
A next-generation sequencing (NGS) of the tumoral tissue was subsequently performed and revealed the presence of the YWHAE1-ROS1 fusion...the patient started crizotinib (250 mg orally, twice daily) as off-label therapy in May 2019. After only 7 days of treatment, we observed a significant dimensional decrease of the left thigh mass...an outstanding clinical response was observed...
DOI:
https://doi.org/10.3389/fonc.2021.658327
